Search Results - "ANTMAN, K"

Introduction: The History of Arsenic Trioxide in Cancer Therapy by Antman, Karen H.

“…Although arsenic can be poisonous, and chronic arsenic exposure from industrial or natural sources can cause serious toxicity, arsenic has been used…”
Get full text

International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas : Report of the jury by SHIPP, M. A, ABELOFF, M. D, SYMANN, M, ARMITAGE, J. O, PHILIP, T, COIFFIER, B, ANTMAN, K. H, CARROLL, G, HAGENBEEK, A, LOEFFLER, M, MONTSERRAT, E, RADFORD, J. A, SALLES, G, SCHMITZ, N

Get full text

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America by Antman, K H, Rowlings, P A, Vaughan, W P, Pelz, C J, Fay, J W, Fields, K K, Freytes, C O, Gale, R P, Hillner, B E, Holland, H K, Kennedy, M J, Klein, J P, Lazarus, H M, McCarthy, Jr, P L, Saez, R, Spitzer, G, Stadtmauer, E A, Williams, S F, Wolff, S, Sobocinski, K A, Armitage, J O, Horowitz, M M

“…To identify trends in high-dose therapy with autologous hematopoietic stem-cell support (autotransplants) for breast cancer (1989 to 1995). Analysis of…”
Get more information

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients by Grann, V R, Panageas, K S, Whang, W, Antman, K H, Neugut, A I

“…Young Ashkenazi Jewish women or those from high-risk families who test positive for BRCA1 or BRCA2 mutant genes have a significant risk of developing breast or…”
Get more information

Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference by Hassan, R, Alexander, R, Antman, K, Boffetta, P, Churg, A, Coit, D, Hausner, P, Kennedy, R, Kindler, H, Metintas, M, Mutti, L, Onda, M, Pass, H, Premkumar, A, Roggli, V, Sterman, D, Sugarbaker, P, Taub, R, Verschraegen, C

“…Peritoneal mesothelioma is a rare cancer of the peritoneum with about 250 new cases diagnosed each year in the United States. It is the second most common site…”
Get full text

Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk by Frank, T S, Manley, S A, Olopade, O I, Cummings, S, Garber, J E, Bernhardt, B, Antman, K, Russo, D, Wood, M E, Mullineau, L, Isaacs, C, Peshkin, B, Buys, S, Venne, V, Rowley, P T, Loader, S, Offit, K, Robson, M, Hampel, H, Brener, D, Winer, E P, Clark, S, Weber, B, Strong, L C, Thomas, A

“…Previous studies of mutations in BRCA1 or BRCA2 have used detection methods that may underestimate the actual frequency of mutations and have analyzed women…”
Get more information

Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation by Hesdorffer, C, Ayello, J, Ward, M, Kaubisch, A, Vahdat, L, Balmaceda, C, Garrett, T, Fetell, M, Reiss, R, Bank, A, Antman, K

“…Normal bone marrow cells have little or no expression of the MDR p-glycoprotein product and, therefore, are particularly susceptible to killing by…”
Get more information

The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma by Renshaw, A A, Dean, B R, Antman, K H, Sugarbaker, D J, Cibas, E S

“…Treatment of malignant mesothelioma (MM) at an early stage results in increased survival. Cytologic examination of pleural effusions is one of the first…”
Get more information

Natural history and epidemiology of malignant mesothelioma by Antman, K H

“…Asbestos exposure constitutes the primary cause of pleural and peritoneal mesothelioma in humans. Risk relates to the duration and intensity of exposure. Thus,…”
Get more information

Adjuvant therapy of sarcomas of soft tissue by Antman, K H

“…Adjuvant chemotherapy for rhabdomyosarcomas, osteosarcomas, and Ewing's sarcomas is established, but remains controversial in other adult sarcomas. Of the 14…”
Get more information

A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer by Antman, K.H.

“…Data from 11 randomised studies on high-dose chemotherapy for breast cancer are currently available. Most investigators, patients and insurers would agree that…”
Get full text

Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma by Sugarbaker, D J, Strauss, G M, Lynch, T J, Richards, W, Mentzer, S J, Lee, T H, Corson, J M, Antman, K H

“…We studied a multimodality approach using extrapleural pneumonectomy, chemotherapy, and radiotherapy in patients with malignant pleural mesothelioma. From 1980…”
Get more information

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas by Antman, K, Crowley, J, Balcerzak, S P, Rivkin, S E, Weiss, G R, Elias, A, Natale, R B, Cooper, R M, Barlogie, B, Trump, D L

“…Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas. Ifosfamide is active in sarcomas that…”
Get more information

Critique of the high-dose chemotherapy studies in breast cancer : A positive look at the data by ANTMAN, K. H

Get full text

Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial by Lew, M A, Kehoe, K, Ritz, J, Antman, K H, Nadler, L, Kalish, L A, Finberg, R

“…To compare the efficacy and safety of ciprofloxacin (CIP) and trimethoprim/sulfamethoxazole (TMS) for the prevention of bacterial infections in patients who…”
Get more information

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression by Antman, K S, Griffin, J D, Elias, A, Socinski, M A, Ryan, L, Cannistra, S A, Oette, D, Whitley, M, Frei, 3rd, E, Schnipper, L E

“…An increase in the dose of chemotherapy enhances the response of many experimental and clinical cancers, but the extent of dose escalation is often limited by…”
Get more information

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy by Antman, K, Ayash, L, Elias, A, Wheeler, C, Hunt, M, Eder, J P, Teicher, B A, Critchlow, J, Bibbo, J, Schnipper, L E

“…The study was designed to determine the duration of complete response (CR) for patients with unresectable or metastatic breast cancer treated with high-dose…”
Get more information

Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy by Elias, A, Ryan, L, Sulkes, A, Collins, J, Aisner, J, Antman, K H

“…In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with…”
Get more information

Malignant mesothelioma following treatment for Hodgkin's disease by Weissmann, L B, Corson, J M, Neugut, A I, Antman, K H

“…Asbestos exposure is the major known risk factor for mesothelioma, but several case reports have suggested a link between radiation therapy and subsequent…”
Get more information

Benefits and Costs of Screening Ashkenazi Jewish Women for BRCA1 and BRCA2 by GRANN, V. R, WHANG, W, JACOBSON, J. S, HEITJAN, D. F, ANTMAN, K. H, NEUGUT, A. I

“…To determine the survival benefit and cost-effectiveness of screening Ashkenazi Jewish women for three specific BRCA1/2 gene mutations. We used a Markov model…”
Get full text